Conversely, RIPK2/MKK7/c-Myc pathway inhibition by GSK583 (a preclinical RIPK2-selective inhibitor) or ponatinib (an existing FDA-approved drug) suppressed PC cell invasion and colony formation, inhibited PC metastatic outgrowth, and did not cause discernable toxicity in mice. This evidence concerns the gene MAP2K7 and pachyonychia congenita.